Houston voices

UH experts weigh in on the funding gap for female researchers

Universities need to make sure all faculty who want to work with the private sector have a chance to succeed, regardless of their gender or discipline. Miguel Tovar/University of Houston

The researchers had a hypothesis. Women faculty, they predicted, would be more successful than their male counterparts at earning private funding – from industry, from nonprofit groups, from charitable endowments. That was about relationships, after all, an area where the popular literature suggests women excel.

The numbers told a different story.

A review of faculty research funding conducted by the Center for ADVANCING Faculty Success at the University of Houston – funded by the National Science Foundation to help recruit and retain female faculty, and especially women of color, in STEM fields – found that women and men had similar success rates when competing for funding from federal agencies. With industry funding, however, the disparities were greater.

"It's about networking," says Christiane Spitzmueller, an industrial psychologist and managing director of the UH center. "Men do more of that. Women aren't primed as much for networking and self-marketing."

No one tracks the numbers nationally, and not all universities report a gender disparity. What is clear is that working with industry and nonprofit groups has drawn new attention in academia amid concerns about stagnant or dropping levels of federal research funding and increasing academic interest in finding solutions to some of society's thorniest problems. To take full advantage of the opportunities, universities need to make sure all faculty who want to work with the private sector have a chance to succeed, regardless of their gender or discipline.

Opportunity knocks

Industry needs these partnerships, too.

"Companies are realizing to be competitive, particularly in high-tech domains, they can't rely on only their internal resources," says Jeff Fortin, associate vice president for research and director of Research and Industrial Partnerships at Pennsylvania State University. "They have to look to universities and other external sources to fill that pipeline of innovation."

Some researchers are already fully engaged with industry. Others aren't interested.

Then there is the middle group. "They would like to engage more with companies," Fortin says. "They haven't done it much, and they need more help, explaining how the process works, the contracting."

His office – and those at other universities seeking to increase their interactions with the private sector – can help.

How to approach industry

Research administrators can help by developing policies for intellectual property, licensing and royalty issues that arise from academic-industry partnerships. Companies want to know how those issues will be handled upfront.

Ultimately, however, it's about the individual faculty member. And it requires persistence.

"The big thing is not to sell yourself short," says Rebecca Carrier, professor of chemical engineering at Northeastern University. "Maybe they're not going to be interested in precisely what you want to work on, but they might be interested in a variation of it."

Look for common goals. And prepare for a different type of relationship.

What to expect

Federal funding agencies generally require an annual report, with little or no interaction at other times. Not so with industry funding.

"When you're working on a project industry cares about, you may report in every six months, or conduct monthly or biweekly teleconferences. You may collaborate with their researchers. You may send your students to their site," says Elyse Rosenbaum, Melvin and Anne Louise Hassebrock Professor in Electrical and Computer Engineering at the University of Illinois-Urbana-Champaign. Rosenbaum also is director of the Center for Advanced Electronics through Machine Learning, a National Science Foundation Industry/University Cooperative Research Center.

Sometimes the work is about solving a specific industry problem, whether that's high workforce turnover or limiting methane emissions on oilfield drilling rigs. Sometimes, as Samira Ali, an assistant professor at the University of Houston Graduate College of Social Work, discovered with her first industry grant, the goal is more global.

Ali is directing one of three centers that are part of a $100 million, 10-year initiative from Gilead Sciences Inc. to address HIV/AIDS in the southern United States.

The payoff

Ali had never worked with industry funding, but the project was a good fit with her research interests. It also wasn't something the federal government would be likely to fund, making the partnership a pragmatic choice.

Another benefit? Carrier, who is director of the Advanced Drug Delivery Lab at Northeastern, says connecting with industry ensures she remains focused on real-world problems.

Working with the private sector is a constant reminder of the end goal – in Carrier's case, finding answers to questions about the mucosal barrier in the intestine, with an eye toward enhancing the absorption of medications and nutrients, as well as understanding links between the gut and overall health.

"It's important to stay in touch and in tune with people who are trying to make a product so that I know what I'm doing matters," she says.

The 411 in industry funding

What type of projects?

  • Short-term, often for a period of one year
  • Practical, focused on a specific product or project
  • Industry support for basic science is unusual but not unheard of

How is it different for government funding?

  • Generally less money, for a shorter period of time
  • Fewer restrictions but can require more flexibility
  • More contact, from biannual or monthly conference calls to sending researchers to work at the company, or having their researchers come to your lab
  • A new vocabulary. Terms understood to mean one thing by researchers and federal funding agencies may be used differently by industry

How to connect?

  • Network. Attend conferences that are important to the industry with which you'd like to work.
  • Educate yourself about the problems a particular industry needs to solve, and think about what solutions you may be able to offer
  • Be persistent and don't be afraid of rejection
  • Take advantage of personal connections – friends, neighbors and former classmates who work in industry may help you connect on specific projects

------

This article originally appeared on the University of Houston's The Big Idea.

Jeannie Kever works with the UH division of research as a senior media relations specialist.

Trending News

Building Houston

 
 

A Rice research team is tapping into materials science to better understand Alzheimer’s disease, a UH professor is developing a treatment for hereditary vision loss, and a BCM researcher is looking at stress and brain cancer. Photo by Gustavo Raskosky/Rice University

Research, perhaps now more than ever, is crucial to expanding and growing innovation in Houston — and it's happening across the city right under our noses.

In InnovationMap's latest roundup of research news, three Houston institutions are working on life-saving health care research thanks to new technologies.

Rice University scientists' groundbreaking alzheimer's study

Angel Martí (right) and his co-authors (from left) Utana Umezaki and Zhi Mei Sonia He have published their latest findings on Alzheimer’s disease. Photo by Gustavo Raskosky/Rice University

According to the Centers for Disease Control and Prevention, Alzheimer’s disease will affect nearly 14 million people in the U.S. by 2060. A group of scientists from Rice University are looking into a peptide associated with the disease, and their study was published in Chemical Science.

Angel Martí — a professor of chemistry, bioengineering, and materials science and nanoengineering and faculty director of the Rice Emerging Scholars Program — and his team have developed a new approach using time-resolved spectroscopy and computational chemistry, according to a news release from Rice. The scientists "found experimental evidence of an alternative binding site on amyloid-beta aggregates, opening the door to the development of new therapies for Alzheimer’s and other diseases associated with amyloid deposits."

Amyloid plaque deposits in the brain are a main feature of Alzheimer’s, per Rice.

“Amyloid-beta is a peptide that aggregates in the brains of people that suffer from Alzheimer’s disease, forming these supramolecular nanoscale fibers, or fibrils” says Martí in the release. “Once they grow sufficiently, these fibrils precipitate and form what we call amyloid plaques.

“Understanding how molecules in general bind to amyloid-beta is particularly important not only for developing drugs that will bind with better affinity to its aggregates, but also for figuring out who the other players are that contribute to cerebral tissue toxicity,” he adds.

The National Science Foundation and the family of the late Professor Donald DuPré, a Houston-born Rice alumnus and former professor of chemistry at the University of Louisville, supported the research, which is explained more thoroughly on Rice's website.

University of Houston professor granted $1.6M for gene therapy treatment for rare eye disease

Muna Naash, a professor at UH, is hoping her research can result in treatment for a rare genetic disease that causes vision loss. Photo via UH.edu

A University of Houston researcher is working on a way to restore sight to those suffering from a rare genetic eye disease.

Muna Naash, the John S. Dunn Endowed Professor of biomedical engineering at UH, is expanding a method of gene therapy to potentially treat vision loss in patients with Usher Syndrome Type 2A, or USH2A, a rare genetic disease.

Naash has received a $1.6 million grant from the National Eye Institute to support her work. Mutations of the USH2A gene can include hearing loss from birth and progressive loss of vision, according to a news release from UH. Naash's work is looking at applying gene therapy — the introduction of a normal gene into cells to correct genetic disorders — to treat this genetic disease. There is not currently another treatment for USH2A.

“Our goal is to advance our current intravitreal gene therapy platform consisting of DNA nanoparticles/hyaluronic acid nanospheres to deliver large genes in order to develop safe and effective therapies for visual loss in Usher Syndrome Type 2A,” says Naash. “Developing an effective treatment for USH2A has been challenging due to its large coding sequence (15.8 kb) that has precluded its delivery using standard approaches and the presence of multiple isoforms with functions that are not fully understood."

BCM researcher on the impact of stress

This Baylor researcher is looking at the relationship between stress and brain cancer thanks to a new grant. Photo via Andriy Onufriyenko/Getty Images

Stress can impact the human body in a number of ways — from high blood pressure to hair loss — but one Houston scientist is looking into what happens to bodies in the long term, from age-related neurodegeneration to cancer.

Dr. Steven Boeynaems is assistant professor of molecular and human genetics at Baylor College of Medicine. His lab is located at the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, and he also is a part of the Therapeutic Innovation Center, the Center for Alzheimer’s and Neurodegenerative Diseases, and the Dan L Duncan Comprehensive Cancer Center at Baylor.

Recently, the Cancer Prevention and Research Institute of Texas, or CPRIT, awarded Boeynaems a grant to continue his work studying how cells and organisms respond to stress.

“Any cell, in nature or in our bodies, during its existence, will have to deal with some conditions that deviate from its ideal environment,” Boeynaems says in a BCM press release. “The key issue that all cells face in such conditions is that they can no longer properly fold their proteins, and that leads to the abnormal clumping of proteins into aggregates. We have seen such aggregates occur in many species and under a variety of stress-related conditions, whether it is in a plant dealing with drought or in a human patient with aging-related Alzheimer’s disease."

Now, thanks to the CPRIT funding, he says his lab will now also venture into studying the role of cellular stress in brain cancer.

“A tumor is a very stressful environment for cells, and cancer cells need to continuously adapt to this stress to survive and/or metastasize,” he says in the release.

“Moreover, the same principles of toxic protein aggregation and protection through protein droplets seem to be at play here as well,” he continues. “We have studied protein droplets not only in humans but also in stress-tolerant organisms such as plants and bacteria for years now. We propose to build and leverage on that knowledge to come up with innovative new treatments for cancer patients.”

Trending News